Daptomycin

A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Also Known As:

Cubicin; Daptomycin, 9-L beta-Aspartic Acid; Deptomycin; LY-146032; Daptomycin, 9 L beta Aspartic Acid; LY 146032; LY146032; N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine-epsilon1-lactone

Networked: 1702 relevant articles (251 outcomes, 252 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Rybak, Michael J: 56 articles (03/2022 - 05/2003)
2.	Sakoulas, George: 42 articles (01/2020 - 05/2003)
3.	Bayer, Arnold S: 29 articles (01/2022 - 01/2008)
4.	Lamp, Kenneth C: 26 articles (01/2018 - 12/2006)
5.	Arias, Cesar A: 24 articles (12/2021 - 11/2007)
6.	Rose, Warren E: 21 articles (01/2022 - 08/2007)
7.	Hamed, Kamal: 14 articles (01/2020 - 04/2015)
8.	Nicolau, David P: 13 articles (01/2021 - 09/2003)
9.	Tascini, Carlo: 12 articles (01/2022 - 04/2010)
10.	Kullar, Ravina: 12 articles (01/2020 - 06/2011)

Related Diseases

1.	Infections 12/01/2010 - "Additional controlled trials will be helpful in identifying the best strategies when using daptomycin to treat CSF infections." 01/01/2020 - "The objective of this study was to evaluate the efficacy of various daptomycin dosing regimens against Staphylococcus aureus and Enterococcus faecium in pediatric patients with proven/suspected gram-positive infection. " 01/01/2010 - "At the time of the introduction of daptomycin into clinical practice in Australia and New Zealand, this agent retains full activity and holds promise as an important therapeutic agent for treating serious Gram positive infections, including strains resistant to multiple other drug classes." 10/26/2023 - "Daptomycin shows promising results in treating infection, offering a good safety profile and a reduced risk of developing resistance. " 11/01/2021 - "The efficacy of high-dose daptomycin and limited safety concerns encourage clinicians to consider high-dose daptomycin more liberally in severe gram-positive infections."
2.	Endocarditis 02/01/2012 - "Our experience suggests that high-dose daptomycin may be a safe therapeutic option in staphylococcal CIED endocarditis and may be associated with high microbiological responses and clinical success." 07/01/2009 - "Daptomycin shows a good therapeutic efficacy in staphylococcal endocarditis: MRSA 71%, MSSA 75%. " 11/01/2008 - "Daptomycin has great promise in this regard as its rapid bactericidal activity makes it particularly suitable for the treatment of bacteraemia and endocarditis." 02/01/2012 - "Daptomycin at the dose of 6 mg/kg/day has been found to be effective in staphylococcal endocarditis, but limited data exist on CIED endocarditis. " 07/01/2008 - "Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus."
3.	Bacteremia 03/01/2022 - "Daptomycin was well tolerated, exhibited a favorable safety profile, and was effective for the treatment of cSSTI or bacteremia in Japanese children." 01/01/2018 - "Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia." 01/01/2018 - "Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia." 12/01/2013 - "Time to clearance of bacteremia, 6-month mortality, and adverse events (AEs) ascribable to daptomycin were also assessed. " 12/01/2021 - "Our study based on PTAs suggests that doses ≥ 6 mg/kg/day of daptomycin should be used to treat bacteremia caused by MRSA and MRSE in patients with CLCR of 15-29 mL/min/1.73 m2. "
4.	Osteomyelitis 07/01/2013 - "This analysis suggests that daptomycin is an effective and well-tolerated treatment option for osteomyelitis and highlights the importance of optimal surgical intervention and appropriate microbiological diagnosis for clinical outcomes." 09/01/2015 - "While adult studies suggest intravenous (IV) daptomycin may by beneficial for the treatment of MRSA osteomyelitis, it is not Food and Drug Administration approved for use in pediatrics, and minimal data are available related to its use in this population. " 01/01/2016 - "Daptomycin appears well tolerated and effective for osteomyelitis treatment. " 09/01/2015 - "While daptomycin was effective in this patient, additional research is needed to determine the true safety and efficacy of this drug for treatment of osteomyelitis caused by MRSA in pediatric patients. " 06/12/2012 - "Daptomycin appears to be an effective therapeutic choice with an acceptable safety profile in the management of osteomyelitis that does not involve hardware."
5.	Sepsis (Septicemia) 08/01/2009 - "These data suggest that daptomycin could be useful for the treatment of bloodstream infections caused by staphylococci." 01/01/2021 - "Large and randomized studies are necessary to ensure daptomycin's safety and efficacy for the treatment of infants with persistent sepsis caused by Gram-positive bacteria." 06/01/2014 - "Concerns regarding the efficacy of daptomycin for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections in patients with impaired renal function are reflected in a recent package insert change by the Food and Drug Administration (FDA). " 01/01/2022 - "The CLSI recommended high-dose daptomycin (8-12 mg/kg) for treating Enterococcus faecium bloodstream infections (BSI). " 01/01/2022 - "Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin."

Related Drugs and Biologics

1.	Vancomycin
2.	Anti-Bacterial Agents (Antibiotics)
3.	Rifampin (Rifampicin)
4.	Linezolid (Zyvox)
5.	Methicillin (Metin)
6.	Ceftaroline
7.	Tigecycline (Tygacil)
8.	Ceftriaxone (Ceftriaxon)
9.	Ampicillin (Omnipen)
10.	Lipopeptides

Related Therapies and Procedures

1.	Therapeutics
2.	Catheters
3.	Culture Diffusion Chambers
4.	Salvage Therapy
5.	Prostheses and Implants (Prosthesis)